Patents Assigned to CSL Ltd.
  • Methods of administering inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 11345759
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 31, 2022
    Assignees: CSL Behring GmbH, CSL Ltd
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
    Patent number: 10513560
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: December 24, 2019
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Factor XII inhibitors for the treatment of neurological inflammatory disorders
    Patent number: 9957329
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 1, 2018
    Assignees: CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg, Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto
    Patent number: 9878017
    Abstract: The present invention relates to a covalent complex of von Willebrand Factor (VWF) and Factor VIII, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: January 30, 2018
    Assignee: CSL Ltd.
    Inventors: Hubert Metzner, Stefan Schulte, Thomas Weimer
  • Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
    Patent number: 9856326
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies
    Patent number: 9856325
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20170137536
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 18, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
    Publication number: 20170121423
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses
    Patent number: 9518127
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 13, 2016
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte